Glaucoma is not seen at a higher prevalence in age-related transthyretin amyloidosis after race stratification

Click to increase image sizeClick to decrease image size

Acknowledgments

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Disclosure statement

NE reports no conflicts. MM reports grants and personal fees from Alnylam, Pfizer, Eidos, Prothena, and Ionis; and personal fees from AstraZeneca, Akcea, Intellia, and Novo-Nordisk. AD institutional research funding from Abbvie, Caelum, Janssen, Novartis, Prothena, Regeneron TeneoBio, consulting/advisory board fees with BMS, Janssen, Kedrion, Pfizer, Prothena.

Author contributions

NE contributed to the study design, created the query, conducted analysis, and wrote the first draft of the paper. MM reviewed the analysis and edited the manuscript. AD designed the study, reviewed the analysis, and co-wrote the manuscript. All authors reviewed and approved the final draft.

Additional information

Funding

Research reported in this publication was supported by R01HL166339 (Dr D’Souza). Dr Mauer is supported by R01HL139671 and R01AG081582-01.